N. Miu *, Dana Fedorczuk *, Cristina Mari, Lia Supuran **
* Prof. Dr. Nicolae Miu, Dr. Dana Fedorczuk, Dr. Cristina Mari – Clinica Pediatrie II Cluj-Napoca
** Lia Supuran – Reprezentanța Vifor (International) Inc. Elveția: Alsifcom Intermed Cluj-Napoca
Abstract
The aim of this prescription trial is to asses the therapeutical efficacy of iron (III) – hydroxide polymaltose complex (Ferrum Hausmann syrup), the tolerability to iron (III) – hydroxide polymaltose complex and the patients’ compliance to the treatment. 57 children aged between 3 – 12 years, suffering from iron deficiency anaemia, were included in this trial. The daily oral dosage was 4 mg iron/bodyweight. The haematological parameters (haemoglobine value, haematocrit, erythrocytes number, MCV) and the adverse events were assesed at the baseline and then monthly during the treatment, and the serrum feritin was evaluated at baseline and at the end of the trial. The results showed that, after a mean period of treatment of 3 months, the haematological parameters normalisation and the increase of iron stores were achieved, demonstrating the bioavailability of iron from this complex. The low incidence of adverse events and the good tolerability of the patients lead to a good compliance.